Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“In the survival analysis, patients with c‐MET overexpression had significantly shorter overall survival (39 vs. 27 months; P = .018) and progression‐free survival (PFS) during bevacizumab treatment (10 vs. 7 months; P = .024).”